


### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the above-identified application.

### **Listing of Claims**

Claims 1-20 are cancelled.

21 (New). A compound which is 8-chloro-3-pentyl-3,7-dihydro-1*H*-purine- 2,6-dione:



a pharmaceutically acceptable salt or solvate thereof.

22 (New). A compound according to claim 21, where the compound is 8-chloro-3-pentyl-3,7-dihydro-1*H*-purine- 2,6-dione.

23 (New). A pharmaceutical formulation, which comprises a compound according to claim 21, and one or more physiologically acceptable diluents, excipients or carriers.

24 (New). A method for treatment of a lipid metabolism disorder or disease, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human or animal subject.

25 (New). The method for treatment of a lipid metabolism disorder or disease according to claim 24, wherein the lipid metabolism disorder or disease is selected from dyslipidaemia, hyperlipoproteinaemia, hypercholesterolaemia or hypertriglyceridaemia.